-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Chemical Machinery Equipment Network Market Analysis ] Recently, with the disclosure of the 2020 annual reports of major listed companies, the performance of the pharmaceutical equipment industry has also surfaced.
On the whole, the annual performance of pharmaceutical machinery companies is relatively good.
In 2020, head medicine companies represented by Teflon, Chutian Technology, and Canaan Technology have all increased their performance year-on-year, with revenues exceeding 1 billion yuan.
The competition among leading companies is also becoming increasingly fierce.
In terms of net profit, Tofflon's net profit in 2020 will be approximately 483 million yuan, and Chutian Technology will also exceed 100 million yuan.
Chemical machinery and equipment network market analysis chemical machinery and equipmentOn the whole, the annual performance of pharmaceutical machinery companies is relatively good.
In 2020, head medicine companies represented by Teflon, Chutian Technology, and Canaan Technology have all increased their performance year-on-year, with revenues exceeding 1 billion yuan.
The competition among leading companies is also becoming increasingly fierce.
In terms of net profit, Tofflon's net profit in 2020 will be approximately 483 million yuan, and Chutian Technology will also exceed 100 million yuan.
The performance of the pharmaceutical equipment industry surfaced
On the evening of March 30, Dong Fulong released the 2020 annual results bulletin.
Total operating income was about 2.
773 billion yuan, an increase of 22.
50% year-on-year; the net profit attributable to shareholders of listed companies was about 483 million yuan, an increase of 231.
13% year-on-year; basic earnings per share were 0.
77 Yuan, an increase of 234.
78% year-on-year.
Total operating income was about 2.
773 billion yuan, an increase of 22.
50% year-on-year; the net profit attributable to shareholders of listed companies was about 483 million yuan, an increase of 231.
13% year-on-year; basic earnings per share were 0.
77 Yuan, an increase of 234.
78% year-on-year.
According to the announcement, during the reporting period, the company vigorously promoted the layout and investment in the three major sectors of "pharmaceutical equipment", "medical technology and technology", and "food equipment engineering" around the development strategy of "systematization, optimization and digitization"; continuous research and development Maintain new products while maintaining iterative updates of existing products; quickly respond to customer needs and maintain effective communication to lay a solid stone for the smooth delivery of system projects; implement precise management concepts, implement digital transformations, and improve management levels.
No*Coincidentally, on February 27, Canaan Technology's 2020 annual performance report showed that in 2020, the company achieved total operating income of 1.
005 billion yuan, an increase of 42.
99% over the same period of the previous year; total realized profit of 88,840,400 yuan, compared with the previous year An increase of 15.
18% over the same period; net profit attributable to shareholders of listed companies was 67.
598 million yuan, an increase of 31.
73% over the same period of the previous year.
005 billion yuan, an increase of 42.
99% over the same period of the previous year; total realized profit of 88,840,400 yuan, compared with the previous year An increase of 15.
18% over the same period; net profit attributable to shareholders of listed companies was 67.
598 million yuan, an increase of 31.
73% over the same period of the previous year.
The main reason for the changes in Canaan Technology’s performance is: During the reporting period, the company continued to strengthen the "solid preparation smart factory overall solution provider" and the strategic orientation of the big health, to fully guarantee the advancement of pharmaceutical equipment and smart logistics industry projects.
At the same time, the company continues to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses across the industry chain to ensure that the company's sales and operating results continue to maintain steady growth.
At the same time, the company continues to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses across the industry chain to ensure that the company's sales and operating results continue to maintain steady growth.
In addition, Chutian Technology’s 2020 annual report is scheduled to be disclosed on April 24, 2021.
However, on January 30, the company issued a performance increase announcement.
It is estimated that the net profit attributable to shareholders of listed companies in 2020 is 183 million-222 million yuan, year-on-year Increased by 180%-240% (after reorganization).
However, on January 30, the company issued a performance increase announcement.
It is estimated that the net profit attributable to shareholders of listed companies in 2020 is 183 million-222 million yuan, year-on-year Increased by 180%-240% (after reorganization).
The performance increase announcement shows that the company adheres to the "one vertical, one horizontal, one platform" strategy, actively responds to customer needs, and effectively guarantees the delivery of orders.
At the same time, in recent years, the company has continued to increase R&D investment, strengthened the construction of process manufacturing platforms, and promoted internal management changes.
The company's product line technology and product performance have been steadily improved, and competitive advantages have gradually emerged.
In addition, during the reporting period, the merger of ROMACO Group was completed, which further promoted the company's strategic layout.
At the same time, in recent years, the company has continued to increase R&D investment, strengthened the construction of process manufacturing platforms, and promoted internal management changes.
The company's product line technology and product performance have been steadily improved, and competitive advantages have gradually emerged.
In addition, during the reporting period, the merger of ROMACO Group was completed, which further promoted the company's strategic layout.
On the whole, the performance of the pharmaceutical equipment industry in 2020 is relatively good.
Many pharmaceutical machinery companies continue to promote their own strategies in 2020, actively respond to market demand and customer needs, and have relatively good operating and financial conditions throughout the year.
Many pharmaceutical machinery companies continue to promote their own strategies in 2020, actively respond to market demand and customer needs, and have relatively good operating and financial conditions throughout the year.
Industry status and trends
From the above-mentioned actions and measures taken by the pharmaceutical machinery companies during the reporting period, we can also glimpse the development status and trends of the domestic pharmaceutical equipment industry.
First, market competition is fierce, and new products are ready to emerge.
In recent years, the homogeneity of products in my country's pharmaceutical equipment market has been serious, and leading companies cannot avoid it.
In addition, the market is changing rapidly, especially in the context of the normalization of centralized procurement, the requirements of pharmaceutical companies on the production capacity of pharmaceutical equipment are changing, and pharmaceutical companies need to make timely response measures, continue to develop new technologies and new products, and improve and upgrade the current situation.
There are equipment.
In recent years, the homogeneity of products in my country's pharmaceutical equipment market has been serious, and leading companies cannot avoid it.
In addition, the market is changing rapidly, especially in the context of the normalization of centralized procurement, the requirements of pharmaceutical companies on the production capacity of pharmaceutical equipment are changing, and pharmaceutical companies need to make timely response measures, continue to develop new technologies and new products, and improve and upgrade the current situation.
There are equipment.
Second, service quality has become one of the elements of competition, and rapid response to customer needs is more valued by pharmaceutical machinery companies.
At present, users not only pay attention to the quality and technical level of products, but also have increasingly higher requirements for the service quality of suppliers.
Especially in the context of consumption upgrades and the concept of personalized consumption being gradually popularized, the requirements and demands of the pharmaceutical industry have changed, and the demand for pharmaceutical equipment has become more innovative, diversified and personalized.
Therefore, pharmaceutical machinery companies need to continuously improve their pre-sales, in-sales, and after-sales service systems from the perspective of customers.
At present, users not only pay attention to the quality and technical level of products, but also have increasingly higher requirements for the service quality of suppliers.
Especially in the context of consumption upgrades and the concept of personalized consumption being gradually popularized, the requirements and demands of the pharmaceutical industry have changed, and the demand for pharmaceutical equipment has become more innovative, diversified and personalized.
Therefore, pharmaceutical machinery companies need to continuously improve their pre-sales, in-sales, and after-sales service systems from the perspective of customers.
Third, under the digital revolution, pharmaceutical machinery companies are accelerating their transformation.
Affected by a special period in 2020, the digital transformation of manufacturing companies can be said to be an inevitable development trend generally recognized in the industry.
Some pharmaceutical companies have also begun to use digital intelligence technology to accelerate their upgrading and transformation, improve management efficiency, and reduce corporate costs.
, To promote the accelerated development of the industry.
Affected by a special period in 2020, the digital transformation of manufacturing companies can be said to be an inevitable development trend generally recognized in the industry.
Some pharmaceutical companies have also begun to use digital intelligence technology to accelerate their upgrading and transformation, improve management efficiency, and reduce corporate costs.
, To promote the accelerated development of the industry.
Original title: From the performance of the pharmaceutical equipment industry in 2020, look at the status quo and trend of the industry
